Uwe Reinhardt, noted Princeton health economist, has written 2 very interesting pieces on P4P in the NY Times. Last week featured this post – The Uncertainties of Pay-for-Performance . This post has some interesting insights.
Why is it so difficult to apply the intuitively appealing idea of P4P in practice?
The answer is that in health care, performance can no more be easily defined and measured than it is in the corporate setting. There, methodological problems and boardroom politics have frequently made a hash of what is regarded as performance-based compensation of executives — especially in the financial sector.
In the health-care setting, P4P is difficult enough at the methodological level. But as the recent debate on health care has shown, it must also navigate the shoals of political demagoguery before even reaching the rocky shores of our tort system. A serious and wide application of P4P in health care is likely to usher in a new legal specialty devoted to attacking specific quality metrics in the courtroom. That always happens when serious money is at stake.
Reinhardt does an excellent job of defining many of the problems of P4P. Some of the comments provide even more fuel for my fire. I particularly like these observations by disappointed:
Pay for performance metrics are necessitated by overly large bureaucracies. The further one is from the action, the greater the necessity to utilize standardized metrics to assess performance. Management experts have known for some time that overly centralized management has severe limitations and that many decisions and judgements are better left to those closer to the ground. Standardized metrics have their place, but with pay for performance, the standard is too often how to game the metrics system rather than how to deliver quality services. Finally, these type of metrics too often focus on short-term results.
Reinhardt, and others, often ignore the widespread failure of P4P in other fields. This 7-year-old HBR article makes important observations – Pay-for-Performance Doesn’t Always Pay Off
In practice, however, the process of connecting pay to performance may be far trickier that it at first appears, according to HBS professor Michael Beer.
As he discovered when he examined programs in pay-for-performance that were discontinued at Hewlett-Packard, these programs may indeed have an upside—but there is a potential downside lurking, too. The HP experience was eye-opening as well as sobering. Thirteen separate units of the company—at different types of sites, in different states—launched pay-for-performance plans in the early 1990s. Within three years, all had dropped them.
Yet this author still believes that P4P can work.
P4P just sounds so fair and logical that accumulated evidence of its flaws are explained away. Reinhardt and many other colleagues persist in using flawed heuristics. We know that those heuristics lead to missed medical diagnoses. I contend that those who favor P4P are blinded by their religious belief that P4P just must work.
Reinhardt followed his initial piece with a follow-up this week – Basing Pay-for-Performance on Outcomes
He continues to explain why P4P is not yet ready for prime time:
All of these experiments with pay-for-performance are fledgling efforts, because the science of outcome measurement has yet to scale many methodological hurdles. Furthermore, in practice the approach will work only if the providers of health care find them sufficiently accurate and fair to sign on. And economic theory tells us that to make the approach effective, it must be backed with significant financial incentives. So far, in many instances, the sums of money at stake have been rather small.
But one should not underrate the sentinel effect of pay-for-performance. Mere talk of the coming of pay-for-performance is likely to draw the attention of the providers of health care — notably the boards of hospitals — to the importance of patient safety and quality. Beyond talk, some research shows that carefully designed pay-for-performance demonstrably appears to enhance the quality of care.
Reinhardt really wants P4P to work. However, he fails to grasp the totality of medical interactions. Adopting P4P might help standardize care for a few common diseases. He links to an article on diabetes management.
But few physicians care for one disease only, not even sub-sub-specialists. Very few patients have one disease only.
P4P will have implementation difficulties because we cannot define medical care with a numeric outcome. The multidimensional factors that might describe physician quality make measurement almost impossible.
How do we measure diagnostic accuracy? What standard can we use? Do we credit physicians for treating the wrong diagnosis with the proper treatment for that missed diagnosis?
How do we measure the physician patient interaction? This interaction includes history taking, patient education and patient motivation. Some suggest we use patient satisfaction scores, but those have major flaws and suffer from intense grade inflation.
How do we measure an appropriate balancing for the management of 5 (or more) diseases? How do we assess the appropriate prioritization of medications? How do we value decreasing polypharmacy by not treating every performance indicator to its fullest?
How do we value appropriate referrals to palliative care? How do we put a number on excellent comfort care?
We might be able to use complex models to assess large hospitals, but I doubt that any model will work for individual physicians.
What can we measure? Instead of calling them never events, we should report these events and set an acceptable standard. When we show that processes can decrease central line infections (Provonost's checklist) then we can penalize hospitals with unacceptable central line infection rates.
We must thank Reinhardt for showing that P4P is not yet ready for prime time. I hope his 2 pieces will further the discussion and discourage premature adoption of a process that likely will have negative externalities.